News · 26 weeks37-17%
2025-12-142026-06-07
Mix2390d
- SEC Filings12(52%)
- Other11(48%)
Latest news
25 items- SECSEC Form DEFA14A filed by Oragenics Inc.DEFA14A - ORAGENICS INC (0001174940) (Filer)
- SECSEC Form DEF 14A filed by Oragenics Inc.DEF 14A - ORAGENICS INC (0001174940) (Filer)
- PROragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti's Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026. The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit www.sidoti.com/events. Registration is free and you don'
- SECOragenics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ORAGENICS INC (0001174940) (Filer)
- PRORAGENICS PROVIDES INVESTOR UPDATEA MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has continued to execute across all fronts — in the clinic, in the regulatory pipeline, on our balance sheet, and strategically. We have reached a pivotal moment: our Phase IIa clinical trial of ONP-002 is active in Australia, patients are being enrolled and dosed, and we have now signed a Letter of Intent to pursue a licensing agreement for a complementary CNS-related medical device. Our focus is sharper than ever — and the progress we are making reflects that. Below is a full account of what has been
- SECSEC Form PRE 14A filed by Oragenics Inc.PRE 14A - ORAGENICS INC (0001174940) (Filer)
- SECSEC Form 10-Q filed by Oragenics Inc.10-Q - ORAGENICS INC (0001174940) (Filer)
- PROragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic InflammationThe Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB:SIGY) ("Sigyn"), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spe
- SECOragenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ORAGENICS INC (0001174940) (Filer)
- PROragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that Alfred Hospital is now actively enrolling participants in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). To date, four patients have been enrolled and dosed at Mackay Base Hospital in Queensland, Australia, the first site activated in the trial. Concussion and mild traumatic brain injury represent the most prominent neurological condition without an FDA-a
- PROragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that 2 patients and 8 study drug doses have been administered in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of mild traumatic brain injury (mTBI) a.k.a., concussion. Enrollment is progressing at Mackay Base Hospital in Queensland, Australia, the first activated site in the trial, with addition
- SECOragenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ORAGENICS INC (0001174940) (Filer)
- PROragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryMackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that the first patient has been dosed in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). The milestone was achieved at Mackay Hospital in Australia — the first sit
- SECOragenics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Financial Statements and Exhibits8-K - ORAGENICS INC (0001174940) (Filer)
- PROragenics, Inc. Receives Audit Opinion with Going Concern ExplanationSARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on March 16, 2026 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 to the Company's
- SECSEC Form EFFECT filed by Oragenics Inc.EFFECT - ORAGENICS INC (0001174940) (Filer)
- SECAmendment: SEC Form S-3/A filed by Oragenics Inc.S-3/A - ORAGENICS INC (0001174940) (Filer)
- PRORAGENICS FILES ANNUAL REPORT ON FORM 10-KREPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing a shareholder update on key operational and clinical milestones achieved during 2025 and progress made in the first quarter of 2026. The Annual Report on Form 10-K, including audited financial statements fo
- SECSEC Form 10-K filed by Oragenics Inc.10-K - ORAGENICS INC (0001174940) (Filer)
- PRORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATIONFIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia. The visit marks the formal launch of clinical trial operations at the first of three planned trial sites in Australia, including completion of site staff training, protocol orientation, and site regulatory documentation. The remaining two clinical trial sites are currently completing their Research Govern
- SECSEC Form 8-K filed by Oragenics Inc.8-K - ORAGENICS INC (0001174940) (Filer)
- PRORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTIONSARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with the Company's lead candidate ONP-002 and its proprietary intranasal drug delivery platform. The Company's portfolio expansion initiative is being pursued independently of its existing partnership with Recepto
- PROragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in AustraliaAll required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent neurological condition without an FDA-approved therapeutic SARASOTA, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has received final Human Research Ethics Committee (HREC) approval in Australia to commence its Phase IIa clinical trial evaluating its lead drug candidate, ONP-002, for the treatment of concussion also known as mi
- PROragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient CareManagement to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a clinical research conference being held February 2–5, 2026, in Orlando, Florida. "Oragenics is excited to participate in one of the premier global conferences for clinical operations and optimal t
- SECSEC Form S-3 filed by Oragenics Inc.S-3 - ORAGENICS INC (0001174940) (Filer)
OGEN FAQ
5 questionsWhat does Oragenics Inc. do?
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc...Where does OGEN stock trade?
Oragenics Inc. (OGEN) is listed on AMEX.What sector and industry is OGEN in?
Oragenics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to OGEN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OGEN side-by-side with any of them on Quantisnow.How can I track OGEN on Quantisnow?
Quantisnow aggregates Oragenics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OGEN to receive live email and push alerts on every new disclosure.